STOCK TITAN

Blueprint Medicines to Present at 18th Annual Morgan Stanley Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ:BPMC) will have its CEO, Jeff Albers, participate in a virtual fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference on September 16, 2020, at 12:30 p.m. ET. This event focuses on the company's advancements in precision therapies for genomically defined cancers and rare diseases. A live webcast of the presentation can be accessed through the Investors & Media section of their website, with a replay available for 30 days. Blueprint Medicines is known for its innovative approach to developing targeted therapies.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Sept. 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced that Jeff Albers, Blueprint Medicines' Chief Executive Officer, will participate virtually in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 16, 2020 at 12:30 p.m. ET.

A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.

About Blueprint Medicines

Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We have two FDA-approved precision therapies and are currently advancing multiple investigational medicines in clinical development, along with a number of research programs. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-18th-annual-morgan-stanley-global-healthcare-conference-301126765.html

SOURCE Blueprint Medicines Corporation

FAQ

When is Blueprint Medicines presenting at the Morgan Stanley Global Healthcare Conference?

Blueprint Medicines will present on September 16, 2020, at 12:30 p.m. ET.

Who will represent Blueprint Medicines at the conference?

CEO Jeff Albers will participate in the fireside chat.

Where can I watch the Blueprint Medicines conference presentation?

The presentation can be viewed live on Blueprint Medicines' website.

What is the focus of Blueprint Medicines?

Blueprint Medicines specializes in precision therapies for genomically defined cancers and rare diseases.

How long will the webcast replay be available?

The replay of the webcast will be available for 30 days after the presentation.

Blueprint Medicines Corporation

NASDAQ:BPMC

BPMC Rankings

BPMC Latest News

BPMC Stock Data

5.79B
62.62M
0.93%
106.49%
6.96%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE